Opaganib

Opaganib
Legal status
Legal status	Investigational new drug;
Identifiers
	IUPAC name 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;
CAS Number	915385-81-8;
PubChem CID	15604015;
DrugBank	12764;
ChemSpider	13079494;
UNII	DRG21OQ517;
ChEBI	CHEBI:124965;
ChEMBL	ChEMBL2158685;
CompTox Dashboard (EPA)	DTXSID801318727 ;
Chemical and physical data
Formula	C23H25ClN2O
Molar mass	380.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl;
	InChI InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27); Key:CAOTVXGYTWCKQE-UHFFFAOYSA-N;

Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS).^[1] It is under development as a potential treatment agent for several different kinds of cancer.^[2]^[3] Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha.^[1]^[4]

References

1 2 Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML (2022). "Recent Progress in the Development of Opaganib for the Treatment of Covid-19". Drug Design, Development and Therapy. 16: 2199–2211. doi:10.2147/DDDT.S367612. PMC 9288228. PMID 35855741.
↑ Camp ER, Patterson LD, Kester M, Voelkel-Johnson C (September 2017). "Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer". Cancer Biology & Therapy. 18 (9): 640–650. doi:10.1080/15384047.2017.1345396. PMC 5663409. PMID 28686076.
↑ Lewis CS, Voelkel-Johnson C, Smith CD (2018). "Targeting Sphingosine Kinases for the Treatment of Cancer". Advances in Cancer Research. 140: 295–325. doi:10.1016/bs.acr.2018.04.015. ISBN 9780128142233. PMC 6447312. PMID 30060814.
↑ Bergman SJ (31 December 2024). "COVID-19 Treatment: Investigational Drugs and Other Therapies: Introduction, Antiviral Agents, Immunomodulators and Other Investigational Therapies". Medscape. Retrieved 26 January 2025.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

[pmid35855741-1] 1 2 Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML (2022). "Recent Progress in the Development of Opaganib for the Treatment of Covid-19". Drug Design, Development and Therapy. 16: 2199–2211. doi:10.2147/DDDT.S367612. PMC 9288228. PMID 35855741.

[2] Camp ER, Patterson LD, Kester M, Voelkel-Johnson C (September 2017). "Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer". Cancer Biology & Therapy. 18 (9): 640–650. doi:10.1080/15384047.2017.1345396. PMC 5663409. PMID 28686076.

[3] Lewis CS, Voelkel-Johnson C, Smith CD (2018). "Targeting Sphingosine Kinases for the Treatment of Cancer". Advances in Cancer Research. 140: 295–325. doi:10.1016/bs.acr.2018.04.015. ISBN 9780128142233. PMC 6447312. PMID 30060814.

[Bergman_2024-4] Bergman SJ (31 December 2024). "COVID-19 Treatment: Investigational Drugs and Other Therapies: Introduction, Antiviral Agents, Immunomodulators and Other Investigational Therapies". Medscape. Retrieved 26 January 2025.

[1]

[2]

[3]

[4]

This page was redesigned at the edge.

References